fda approval tirzepatide weight loss confirms shortage is still over, gives compounders a grace period 🌟 Introducing Tirzepatide Tablets: A

On May 5, 2025, Hims earnings release and shareholder letter touted personalized solutions like compounded GLP-1s and a generic tiraglutide launch, plus innovative partnerships driving growth

Tirzepatide-related symptoms often improve or fade over time, while gastroparesis symptoms are persistent and require long-term management

weight management for specific formulations like Saxenda and Wegovy) Healthcare professionals should remain vigilant for signs of pancreatitis, which is listed as a known adverse effect in the Summary of Product Characteristics (SmPC) for all GLP-1 agents There is no official link established between GLP-1 therapy and pancreatic cancer based on current evidence NICE guidance for type 2 diabetes management (NG28) continues to recommend GLP-1 receptor agonists as appropriate treatment options when specific criteria are met

But the potential of semaglutide and its relatives as addiction treatments, he says, is real